NovaBay Expands Global Ophthalmology Study of Pink Eye to India
January 03, 2013 07:30 ET
|
NovaBay Pharmaceuticals, Inc.
Phase 2b BAYnovation Study for the Treatment of Viral Conjunctivitis Includes 60 Clinical Sites Worldwide
EMERYVILLE, Calif., Jan. 3, 2013 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc....
NovaBay Pharmaceuticals to Present at Biotech Showcase 2013
December 19, 2012 08:00 ET
|
NovaBay Pharmaceuticals, Inc.
Live Webcast Scheduled for January 8, 2013 at 2:45 pm (PST)
EMERYVILLE, Calif., Dec. 19, 2012 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE MKT:NBY), a biotechnology company...
NovaBay Pharmaceuticals Provides Business Update and 2013 Outlook
December 13, 2012 07:30 ET
|
NovaBay Pharmaceuticals, Inc.
Recent $7 Million Financing to Accelerate and Expand Clinical Trials
Steady Progress Across Four Business Units:
Ophthalmology
Viral conjunctivitis (unmet medical need)
Financing...
NovaBay Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock and Warrants
December 06, 2012 08:55 ET
|
NovaBay Pharmaceuticals, Inc.
EMERYVILLE, Calif., Dec. 6, 2012 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE MKT:NBY), a biotechnology company focused on addressing the large unmet therapeutic needs of the global...
NovaBay Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock and Warrants
December 05, 2012 16:06 ET
|
NovaBay Pharmaceuticals, Inc.
EMERYVILLE, Calif., Dec. 5, 2012 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE MKT:NBY), a biotechnology company focused on addressing the large unmet therapeutic needs of the global...
NovaBay Pharmaceuticals to Present at LD Micro Conference
November 28, 2012 08:00 ET
|
NovaBay Pharmaceuticals, Inc.
EMERYVILLE, Calif., Nov. 28, 2012 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE MKT:NBY), a biotechnology company focused on addressing the large unmet therapeutic needs of the global...
NovaBay Pharmaceuticals Receives Additional $1.5 Million Equity Funding from Pioneer Pharma Co.
November 05, 2012 07:30 ET
|
NovaBay Pharmaceuticals, Inc.
This Completes the First $2.5 Million Tranche of a Potential Total Investment of $5.5 Million
EMERYVILLE, Calif., Nov. 5, 2012 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE:NBY),...
NovaBay Pharmaceuticals Provides Third Quarter 2012 Financial Results
November 01, 2012 06:19 ET
|
NovaBay Pharmaceuticals, Inc.
Enrollment Continues to Advance in Three Phase 2b Clinical Trials for Conjunctivitis, Impetigo and UCBE
Recent Highlights
Global Phase 2b clinical study of lead Aganocide® NVC-422 for...
NovaBay Pharmaceuticals to Present at Lazard Capital Markets 9th Annual Healthcare Conference
October 31, 2012 08:00 ET
|
NovaBay Pharmaceuticals, Inc.
EMERYVILLE, Calif., Oct. 31, 2012 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE MKT:NBY), a biotechnology company focused on addressing the large unmet therapeutic needs of the global...
NovaBay Pharmaceuticals (NBY) Receives $2.6 Million From Partner Galderma
September 26, 2012 07:30 ET
|
NovaBay Pharmaceuticals, Inc.
Marks Advancement of Aganocide® NVC-422 Clinical Program for Impetigo Treatment
EMERYVILLE, Calif., Sept. 26, 2012 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE:NBY), a...